{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Travere Therapeutics, Inc.
Travere Therapeutics Hits New 52-Week High of $35.34, Marking Major Growth
Travere Therapeutics, Inc. has achieved a new 52-week high, reflecting a significant performance increase over the past year. The company, with a market capitalization of USD 1,890 million, has reported a 40.03% rise in net sales and positive results for three consecutive quarters, despite operating losses.
Travere Therapeutics Achieves 100.91% Return, Marking It as a Multibagger in Pharmaceuticals
Travere Therapeutics, Inc. has recently undergone a revision in its score, reflecting its strong performance metrics and market position. The company has achieved significant growth in net sales and has consistently reported positive results over the past quarters, further enhancing its appeal in the Pharmaceuticals & Biotechnology sector.
Travere Therapeutics Hits New 52-Week High of $28.85, Surging 286%
Travere Therapeutics, Inc. has achieved a new 52-week high, reflecting a remarkable performance with a 285.97% increase over the past year. The company reported a 40.03% growth in net sales, totaling USD 114.45 million, and has shown positive results for three consecutive quarters, indicating strong financial health.
Travere Therapeutics, Inc. Reports Strong Financial Performance in Q2 2025
Travere Therapeutics, Inc. reported strong financial results for Q2 2025, showcasing significant growth and operational efficiency. The company achieved record net sales and operating cash flow, alongside improved profit margins and inventory turnover. However, it faced challenges with pre-tax and net profit figures, reflecting ongoing investments in growth.
Is Travere Therapeutics, Inc. technically bullish or bearish?
As of August 5, 2025, Travere Therapeutics, Inc. shows a mildly bullish trend, supported by positive MACD, Bollinger Bands, and moving averages, despite a bearish weekly RSI and mixed Dow Theory signals.
Is Travere Therapeutics, Inc. overvalued or undervalued?
As of November 3, 2016, Travere Therapeutics, Inc. is considered a risky investment due to its overvaluation indicated by a high Price to Book Value of 41.45, negative EV ratios, and significantly negative ROCE and ROE, despite a strong recent stock return that may not be sustainable.
Travere Therapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead
Travere Therapeutics, Inc. has recently achieved a Golden Cross, indicating a potential shift in momentum. The stock displays a bullish outlook across various technical indicators, despite a short-term decline. Over the past year, it has significantly outperformed the S&P 500, suggesting growing investor interest in the biotechnology sector.
Is Travere Therapeutics, Inc. overvalued or undervalued?
As of November 3, 2016, Travere Therapeutics, Inc. is considered risky and overvalued due to troubling financial metrics, including a price-to-book ratio of 41.45 and a return on equity of -681.59%, especially when compared to peers like Innoviva and Collegium Pharmaceutical, and its stock has declined 16.82% year-to-date versus a 2.44% increase in the S&P 500.
Is Travere Therapeutics, Inc. technically bullish or bearish?
As of June 5, 2025, the market trend is mildly bearish due to bearish MACD and moving averages, despite some bullish signals on the monthly chart, indicating weakness in the short to medium term.
What does Travere Therapeutics, Inc. do?
Travere Therapeutics, Inc. is a micro-cap pharmaceutical and biotechnology company with recent net sales of $82 million and a net loss of $41 million. It has a market cap of approximately $1.25 billion and key metrics indicating significant financial challenges, including a debt-to-equity ratio of 1.91 and a return on equity of -681.59%.
How big is Travere Therapeutics, Inc.?
As of Jun 18, Travere Therapeutics, Inc. has a market capitalization of $1.25 billion, with net sales of $273.54 million and a net profit of -$225.90 million over the last four quarters. Shareholder's funds are reported at $59.08 million, and total assets amount to $594.12 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
